Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027508 · ClinicalTrials.gov registry record · Phase 2
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
A Phase 2 study, sponsored by PharmaMar.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00027508: Clinical Trial Phase 2 study, sponsored by PharmaMar.
NCT00027508 is a Phase 2 study that was terminated before completion, run by PharmaMar. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027508, a Phase 2 study, was terminated before completion, sponsored by PharmaMar.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
Interventions
- DRUG trabectedin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
Why NCT00027508 stopped before completion
NCT00027508 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which trabectedin is the first listed.
NCT00027508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027508 about?
NCT00027508 is a clinical study titled "Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
What is the current status of trial NCT00027508?
This trial is currently terminated. It is a Phase 2 study. The study started on 2001-07. Estimated completion is 2002-02.
What interventions are being tested in trial NCT00027508?
The interventions under investigation include: trabectedin (DRUG).
Who is sponsoring clinical trial NCT00027508?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia